The Latest Trading Price of Cipla Ltd is ₹ 1193 as of 02 Apr 15:30
. The P/E Ratio of Cipla Ltd changed from 27.3 on March 2021 to 22.1 on March 2025 . This represents a CAGR of -4.14% over 5 yearsThe P/E Ratio of Mankind Pharma Ltd changed from 48.1 on March 2024 to 50.2 on March 2025 . This represents a CAGR of 2.16% over 2 years The Market Cap of Cipla Ltd changed from ₹ 65746 crore on March 2021 to ₹ 116434 crore on March 2025 . This represents a CAGR of 12.11% over 5 yearsThe Market Cap of Mankind Pharma Ltd changed from ₹ 92029 crore on March 2024 to ₹ 99973 crore on March 2025 . This represents a CAGR of 4.23% over 2 years The revenue of Cipla Ltd for the Dec '25 is ₹ 7280 crore as compare to the Sep '25 revenue of ₹ 7858 crore. This represent the decline of -7.35% The revenue of Mankind Pharma Ltd for the Dec '25 is ₹ 3643 crore as compare to the Sep '25 revenue of ₹ 3791 crore. This represent the decline of -3.91% The ebitda of Cipla Ltd for the Dec '25 is ₹ 1185 crore as compare to the Sep '25 ebitda of ₹ 2163 crore. This represent the decline of -45.21% The ebitda of Mankind Pharma Ltd for the Dec '25 is ₹ 888.8 crore as compare to the Sep '25 ebitda of ₹ 1015 crore. This represent the decline of -12.48% The net profit of Cipla Ltd changed from ₹ 1176 crore to ₹ 674.56 crore over 7 quarters. This represents a CAGR of -27.22%
The net profit of Mankind Pharma Ltd changed from ₹ 543.07 crore to ₹ 413.88 crore over 7 quarters. This represents a CAGR of -14.38%
The Dividend Payout of Cipla Ltd changed from 16.34 % on March 2021 to 25.05 % on March 2025 . This represents a CAGR of 8.92% over 5 yearsThe Dividend Payout of Mankind Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Cipla Ltd
Cipla Limited is one of the leading pharmaceutical companies in India.
The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories.
Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.
About Mankind Pharma Ltd
Mankind Pharma Limited was incorporated on July 3, 1991, as a Private Limited Company with the name 'Mankind Pharma Private Limited', by the Registrar of Companies, Delhi and Haryana, at New Delhi.
Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to 'Mankind Pharma Limited' and the RoC issued a fresh Certificate of Incorporation on April 13, 2006.
The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products.
It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory.
FAQs for the comparison of Cipla Ltd and Mankind Pharma Ltd
Which company has a larger market capitalization, Cipla Ltd or Mankind Pharma Ltd?
Market cap of Cipla Ltd is 96,400 Cr while Market cap of Mankind Pharma Ltd is 82,460 Cr
What are the key factors driving the stock performance of Cipla Ltd and Mankind Pharma Ltd?
The stock performance of Cipla Ltd and Mankind Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Cipla Ltd and Mankind Pharma Ltd?
As of April 3, 2026, the Cipla Ltd stock price is INR ₹1193.4. On the other hand, Mankind Pharma Ltd stock price is INR ₹1997.45.
How do dividend payouts of Cipla Ltd and Mankind Pharma Ltd compare?
To compare the dividend payouts of Cipla Ltd and Mankind Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.